Extended Data Fig. 3: Interval between CSF collection and death for patients with positive (blue) and negative (red) CSF ctDNA.
From: Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid
a, All patients with glioma. Median overall survival (OS): for CSF ctDNA-positive patients, 3.15 months (95% confidence interval, 1.97–4.63); for CSF ctDNA-negative patients, 11.91 months (95% confidence interval, 8.40–30.81). The log-rank P value for comparing the survival experience of all patients with glioma stratified by ctDNA status was 0.0000078675. b, Patients with GBM (IDH WT). Median overall survival: for CSF ctDNA-positive subjects, 2.04 months (95% confidence interval, 0.98–3.77); for CSF ctDNA-negative subjects, 9.89 months (95% confidence interval, 5.54–12.39). The log-rank P value for comparing the survival experience of patients with GBM (IDH WT) by ctDNA status was 0.000062396 (log-rank test, two-sided).
